6 September 2024 in Journal of Investigative Dermatology
5 August 2024 in American Journal of Clinical Dermatology
28 October 2024 in Dermatitis®
Atopic dermatitis (AD) is a highly burdensome inflammatory skin condition affecting nearly one-quarter of the pediatric population and often continuing into adulthood. Despite recent advancements in systemic therapies providing temporary symptom relief over the past decade, AD frequently remains difficult to control, necessitating increased dosages or alternative treatments due to recurrent disease. This review synthesizes current literature to identify unmet needs of treating AD beyond medication-related limitations and evaluates existing therapies for their efficacy in modifying underlying disease mechanisms. Key findings include variability in AD pathophysiology and phenotypes across different age groups and ethnicities, indicating a need for research into endotype-specific treatments. The literature also comprises evidence suggesting that select current drugs, such as targeted biologics and Janus Kinase (JAK) inhibitors, may offer long-term disease-modifying benefits. Future management strategies should explore novel approaches, including manipulation of the microbiome, immune response, and neural function, as these may lead to additional improvements in AD treatment and long-term symptom relief.
13 March 2025 in Journal of Investigative Dermatology
21 January 2024 in JID Innovations
16 July 2024 in Clinical and Experimental Dermatology
We describe an extensive, asymptomatic presentation of a rare condition in a 59-year-old male patient presenting with nonpruritic, nonpainful, hyperpigmented plaques on the upper body. Multiple treatments had failed to resolve the lesions, but with an added JAK inhibitor the patient developed no new lesions. We hope this description contributes to our limited understanding of this rarely reported clinical entity.